During the third quarter of 2026, VERIGRAFT continued to advance its pivotal Phase II/III clinical trial, TECVI-2, while strengthening its international manufacturing capabilities.
Preparations for TECVI-2 progressed in Spain, with clinical site initiation activities underway. In parallel, the company continued preparations for expanding the trial to additional European countries.
VERIGRAFT also advanced its international manufacturing strategy through ongoing collaboration with BioBridge Global in the United States and the addition of Bramble Bio as a European manufacturing partner.
Alongside these developments, the company continued its research and development activities across its broader pipeline of personalized tissue therapies.
These efforts reflect VERIGRAFT’s continued focus on advancing its clinical program and building the capabilities needed for future development and commercialization.